Pembroke Management’s Castle Biosciences CSTL Stock Holding History

Pembroke Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-463,909	Closed	-$20.8M	–	66
2022 Q1	$20.8M	Buy	463,909 +80,537	+21%	+$3.33M	1.74%	26
2021 Q4	$16.4M	Sell	383,372 -50,307	-12%	-$2.63M	1.2%	37
2021 Q3	$28.8M	Sell	433,679 -17,215	-4%	-$1.21M	2.17%	20
2021 Q2	$33.1M	Sell	450,894 -10,328	-2%	-$682K	2.59%	7
2021 Q1	$31.6M	Buy	461,222 +200,976	+77%	+$15.1M	2.63%	8
2020 Q4	$17.5M	Buy	+260,246	New	+$14.1M	1.47%	32

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Pembroke Management's CSTL Position: Q2 2022 in Review

Pembroke Management sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 463,909 shares — an estimated $20.8M sold.

Pembroke Management first reported a position in CSTL in Q4 2020 and held it in 6 quarters. The position peaked at $33.1M in Q2 2021. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

Pembroke Management reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
Pembroke Management sold 463,909 Castle Biosciences shares in Q2 2022, an estimated $20.8M.
Pembroke Management first reported a position in Castle Biosciences in Q4 2020 and held it in 6 quarters.
Pembroke Management's Castle Biosciences position peaked at $33.1M in Q2 2021.
146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Pembroke Management's 13F filing for Q2 2022, filed 26 Jul 2022.